<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746391</url>
  </required_header>
  <id_info>
    <org_study_id>UGent_FiberClotting_2</org_study_id>
    <nct_id>NCT04746391</nct_id>
  </id_info>
  <brief_title>Impact of Clotting on Dialyzer Efficiency</brief_title>
  <official_title>Assessment of a Relation Between Dialyzer Clearance and Clotting in Hemodialyzer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coagulation within the dialyzer membrane fibres is an obvious biological sign of&#xD;
      bio-incompatibility. To avoid clotting during extracorporeal treatment, an anticoagulant is&#xD;
      added to the circuit, resulting in an increased risk for bleeding complications. In addition,&#xD;
      there is evidence that a substantial number of fibers can become blocked before this is&#xD;
      reflected in routinely observed parameters, or in termination of the dialysis session. Little&#xD;
      is known about the impact of such subclinical clotting on dialyzer performance in terms of&#xD;
      solute clearance. Membrane clogging may influence both the diffusive and convective transport&#xD;
      characteristics of the dialyzer membrane before leading to complete dialyzer clotting. In&#xD;
      2018, we described a method to objectively count the number of blocked fibres inside a&#xD;
      dialyzer using a micro-CT scanning technique. In the present trial, we use this method to&#xD;
      assess the number of open fibers post dialysis, and this for three different dialysis&#xD;
      durations and in two different dialyzer types. Just before the termination of the dialysis&#xD;
      session, dialyzer clearance is assessed for different solutes from concentration measurements&#xD;
      in blood samples as taken from the dialyzer inlet and outlet line.&#xD;
&#xD;
      The aim of this randomized cross-over study is to objectively quantify the impact of blocked&#xD;
      fibers on the performance of different dialyzer membranes: ATA™ (asymmetric triacetate)&#xD;
      membrane in the Solacea™ dialyzer, and polysulfone membrane in the FX800Cordiax dialyzer, and&#xD;
      this with a decreased anticoagulation dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single centre, randomized cross-over study includes ten consecutive stable chronic&#xD;
      hemodialysis (HD) patients who experienced stable dialysis sessions during the last 4 weeks,&#xD;
      and had no known coagulation disorder, active inflammation or malignancy. Double-needle&#xD;
      vascular access is achieved through a native arterio-venous fistula or a well-functioning&#xD;
      double lumen tunnelled central venous catheter. Patients are followed during 6 consecutive&#xD;
      midweek dialysis sessions. At midweek, patients receive only 1/4th of their regular brand of&#xD;
      Low-Molecular Weight Heparin anticoagulation at the beginning of the dialysis session. All&#xD;
      test sessions are performed with blood flow at 300mL/min and dialysate flow at 500mL/min in&#xD;
      post dilution hemodiafiltration (HDF) mode (substitution flow 75mL/min). Ultrafiltration&#xD;
      rates are set according to the patient's interdialytic weight gain and clinical status.&#xD;
&#xD;
      Patients are randomized for hemodialyzer type and dialysis duration:&#xD;
&#xD;
        1. ATA™ Solacea 19H - 60min dialysis&#xD;
&#xD;
        2. ATA™ Solacea 19H - 120min dialysis&#xD;
&#xD;
        3. ATA™ Solacea 19H - 240min dialysis&#xD;
&#xD;
        4. polysulfone FX800Cordiax - 60min dialysis&#xD;
&#xD;
        5. polysulfone FX800Cordiax - 120min dialysis&#xD;
&#xD;
        6. polysulfone FX800Cordiax - 240min dialysis&#xD;
&#xD;
      Just before the termination of the 6 experimental midweek sessions, blood is sampled from the&#xD;
      inlet and outlet blood lines. Blood samples are immediately centrifuged and serum vials are&#xD;
      stored at -80°C until batch analysis. Post dialysis, dialyzers are rinsed and dried and&#xD;
      scanned with micro computed tomography (CT) to count the number of open fibers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibre blocking in hemodialyzers</measure>
    <time_frame>6 weeks</time_frame>
    <description>Fibre blocking as assessed post dialysis by a reference microCT scanning technique</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodialyzer performance</measure>
    <time_frame>6 weeks</time_frame>
    <description>Dialyzer performance based on calculated clearances for different solutes</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Coagulation</condition>
  <arm_group>
    <arm_group_label>Solacea_60min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination&#xD;
microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_120min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination&#xD;
microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solacea_240min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination&#xD;
microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_60min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sampling from dialyzer inlet and outlet line at 60min, just before dialysis termination&#xD;
microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_120min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sampling from dialyzer inlet and outlet line at 120min, just before dialysis termination&#xD;
microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FX800_240min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood sampling from dialyzer inlet and outlet line at 240min, just before dialysis termination&#xD;
microCT scanning of rinsed and dried hemodialyzer, post dialysis in order to count open fibers</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dialyzer type</intervention_name>
    <description>Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers</description>
    <arm_group_label>FX800_120min</arm_group_label>
    <arm_group_label>FX800_240min</arm_group_label>
    <arm_group_label>FX800_60min</arm_group_label>
    <arm_group_label>Solacea_120min</arm_group_label>
    <arm_group_label>Solacea_240min</arm_group_label>
    <arm_group_label>Solacea_60min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dialysis duration</intervention_name>
    <description>Fiber blocking and dialyzer clearance is calculated for three different dialysis durations</description>
    <arm_group_label>FX800_120min</arm_group_label>
    <arm_group_label>FX800_240min</arm_group_label>
    <arm_group_label>FX800_60min</arm_group_label>
    <arm_group_label>Solacea_120min</arm_group_label>
    <arm_group_label>Solacea_240min</arm_group_label>
    <arm_group_label>Solacea_60min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  experienced stable dialysis sessions during the last 4 weeks&#xD;
&#xD;
          -  double needle/lumen well-functioning vascular access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known coagulation disorder&#xD;
&#xD;
          -  active inflammation&#xD;
&#xD;
          -  malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Van Biesen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital - Nephrology</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Vanommeslaeghe F, Van Biesen W, Dierick M, Boone M, Dhondt A, Eloot S. Micro-computed tomography for the quantification of blocked fibers in hemodialyzers. Sci Rep. 2018 Feb 8;8(1):2677. doi: 10.1038/s41598-018-20898-w.</citation>
    <PMID>29422614</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialyzer</keyword>
  <keyword>Fibre Clotting</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

